Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
Youwen Zhu, Kun Liu, Dong Ding, Yangying Zhou, Libo Peng
Topics & Concepts
MedicinePembrolizumabCost effectivenessRegimenQuality-adjusted life yearInternal medicineEsophageal cancerCost-effectiveness analysisOncologyWillingness to paySurgeryCancerImmunotherapyRisk analysis (engineering)EconomicsMicroeconomicsEsophageal Cancer Research and TreatmentCancer Immunotherapy and BiomarkersHealth Systems, Economic Evaluations, Quality of Life